Three Seasons Wealth LLC Has $1.41 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Three Seasons Wealth LLC increased its holdings in Eli Lilly and Company by 82.5% during the 1st quarter, making the stock worth $1.41 million as of its latest filing.
• Eli Lilly's stock has a market capitalization of $727.63 billion and a price-to-earnings ratio of 62.47, with shares recently trading at $767.75.
• The company recently announced a quarterly dividend of $1.50 per share, which equates to an annualized yield of 0.8%.

Three Seasons Wealth LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 82.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,710 shares of the company's stock after buying an additional 773 shares during the quarter. Eli Lilly and Company makes up 0.7% of Three Seasons Wealth LLC's holdings, making the stock its 24th biggest position. Three Seasons Wealth LLC's holdings in Eli Lilly and Company were worth $1,412,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Knightsbridge Asset Management LLC raised its stake in Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after acquiring an additional 15 shares during the period. LS Investment Advisors LLC raised its stake in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares during the period. Prism Advisors Inc. bought a new stake in Eli Lilly and Company in the 1st quarter valued at $207,000. CSM Advisors LLC raised its stake in Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after acquiring an additional 245 shares during the period. Finally, Bfsg LLC raised its stake in Eli Lilly and Company by 1.4% in the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after acquiring an additional 42 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.7%

Shares of NYSE:LLY opened at $767.75 on Tuesday. The stock has a market cap of $727.63 billion, a price-to-earnings ratio of 62.47, a PEG ratio of 1.08 and a beta of 0.44. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The business's 50 day moving average is $776.59 and its 200 day moving average is $800.81.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Guggenheim raised their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.